

PROTECTION OF IMIDE GROUP OF URACIL MOIETY BY MEANS OF 2,2,2-TRICHLORO-TERT-BUTYLOXYCARBONYL CHLORIDE: A SELECTIVE SYNTHESIS OF 2'-O-METHYLURIDINE

Takashi KAMIMURA, Tsukio MASEGI, and Tsujiaki HATA*

Department of Life Chemistry, Tokyo Institute of Technology,
Nagatsuta, Midoriku, Yokohama 227


Summary: 2,2,2-Trichloro-tert-butylloxycarbonyl group (TCBOC) was useful protecting group for the protection of imide function of uracil moiety. Starting from N³-TCBOC uridine derivative, 2'-O-methyluridine was selectively synthesized without formation of N³-methyluridine derivatives.

There have been several protecting groups for amino and hydroxyl functions in nucleoside chemistry. However, little attention¹⁾ has been paid to imide group of nucleoside bases. Recently, Reese²⁾ and our laboratory³⁾ have demonstrated some of side reactions which may proceed during the coupling reactions for the synthesis of oligonucleotides. Synthesis of 2'-O-methyluridine exists in the same situation. When the methylation reaction of appropriately protected uridine was performed, methyl groups were introduced not only at the 2'-O-hydroxyl group but also the N³-imide function.⁴⁾ In order to avoid such side reactions, we have to tackle to find out an appropriate protecting group for these groups of nucleoside bases.

After several screenings 2,2,2-trichloro-t-butylloxycarbonyl group (TCBOC) was found to be the most suitable protecting group for the imide function of uracil residue. This group can be introduced in high yield on N³-position of uridine by means of 2,2,2-trichloro-t-butylloxycarbonyl chloride (TCBOC-Cl) which was used as a reagent for protection of amino group of amino acids in peptide synthesis⁵⁾ and is removed by treatment with zinc powder under very mild conditions.

The outline for the synthesis of 2'-O-methyluridine is shown in Scheme 1.

Procedure of each step is described as follows: When uridine (0.63 g, 2.57 mmol) was treated with 1,3-dichloro-1,1,3,3-tetraisopropylidisiloxane (TIPDSiCl₂) (0.85 g, 2.70 mmole) in dry pyridine (20 ml) at room temperature overnight, the corresponding 3',5'-cyclic silylether derivative of uridine (1)⁶⁾ was obtained in 95% yield (1.19 g).



Compound 1 (0.88 g, 1.81 mmole) was further treated with phenoxyacetic anhydride (1.55 g, 5.42 mmole)⁷⁾ in dry pyridine (10 ml) at 0°C. 2'-O-Phenoxyacetyl-3',5'-cyclic silylether derivative (2) was obtained in 87% yield (0.98 g) as a white powder.

¹H-NMR(CDCl₃) δ=1.04, 1.08, 1.10(28, Si-CH(CH₃)₂), 3.86-4.42(4, H-3',4',5'), 4.72 (s, 2, C(O)-CH₂-OPh), 5.48(d, 1, J_{2',3'}=4Hz, H-2'), 5.66(d, 1, J₅₋₆=8Hz, H-5), 5.76(s, 1, H-1'), 6.82-7.30(m, 5, O-Ph), 7.68(d, 1, H-6), 10.10(br.s, 1, H-3). Found: C, 53.09; H, 7.22; N, 4.74%. Calcd for C₂₉H₄₄O₉N₂Si₂·2H₂O: C, 53.03; H, 7.37; N, 4.26%.

Compound 2 (0.98 g, 1.58 mmole) was allowed to react with TCBOC-Cl (0.95 g, 3.94 mmole) in dry pyridine at room temperature overnight to afford the corresponding N³-TCBOC uridine derivative (3) in 83% yield (1.07 g) as a white powder.

¹H-NMR(CDCl₃) δ=1.06, 1.10, 1.12(28, Si-CH(CH₃)₂), 2.10(s, 6, C(CH₃)₂CCl₃), 3.88-4.44(4, H-3',4',5'), 4.70(s, 2, C(O)-CH₂-OPh), 5.50(d, 1, J_{2',3'}=4Hz, H-2'), 5.68 (d, 2, J₅₋₆=8Hz, H-5), 5.72(s, 1, H-1'), 6.82-7.30(m, 5, O-Ph), 7.66(d, 1, H-6). Found: C, 48.55; H, 6.13; N, 3.33; Cl, 12.48%. Calcd for C₃₄H₄₉O₁₁N₂Si₂Cl₃·H₂O: C, 48.48; H, 6.10; N, 3.33; Cl, 12.63%.

The phenoxyacetyl group was selectively removed from the fully protected uridine derivative (3) (0.96 g, 1.16 mmole) by treatment with t-butylamine (0.255 g, or 0.366 ml, 3.49 mmole) in methanol (25 ml) at room temperature for 20 min. The

corresponding 2'-hydroxyl derivative (4) was obtained in 77% yield (0.614 g) as a white powder.

$^1\text{H-NMR}(\text{CDCl}_3)$ δ =1.04, 1.08, 1.10(28, Si-CH(CH₃)₂), 2.08(s, 6, C(CH₃)₂CCl₃), 3.12 (s, 1, OH-2'), 4.04-4.40(5, H-2',3',4',5'), 5.70(s, 1, H-1'), 5.72(d, 1, J₅₋₆=8Hz, H-5), 7.68(d, 1, H-6). Found: C, 45.08; H, 6.36; N, 4.07; Cl, 16.06. Calcd for C₂₆H₄₃O₉N₂Si₂Cl₃: C, 45.25; H, 6.28; N, 4.06; Cl, 15.41%.

Compound 4 (0.5 g, 0.724 mmol) was methylated by use of excess methyl iodide (15.06 g, 0.106 mole) in the presence of silver oxide^{4a)} (0.912 g, 3.93 mmole) under reflux for 7 h. 2'-O-Methylated product (5) was obtained in 93% yield (0.472 g) as a white powder.

$^1\text{H-NMR}(\text{CDCl}_3)$ δ =1.08, 1.12(28, Si-CH(CH₃)₂), 2.10(s, 6, C(CH₃)₂CCl₃), 3.64(s, 3, 2'-OCH₃), 3.74(d, 1, J_{2'-3'}=4Hz, H-2'), 4.04-4.32(4, H-3',4',5'), 5.68(d, 1, J₅₋₆=8Hz, H-5), 5.72(s, 1, H-1'), 7.90(d, 1, H-6). Found: C, 46.21; H, 6.42; N, 3.94; Cl, 14.51%. Calcd for C₂₇H₄₅O₉N₂Si₂Cl₃: C, 46.05; H, 6.44; N, 3.98; Cl, 15.10%.

The TCBoc group was removed by treatment of 5 (0.408 g, 0.579 mmole) with zinc powder (0.568 g, 8.69 mmole) in the presence of acetylacetone⁸⁾ (0.87 g, 8.69 mmole) in dry pyridine (15 ml) at room temperature for 15 min. The deblocked material (6) was obtained in 86% yield (0.25 g) as a white powder.

$^1\text{H-NMR}(\text{CDCl}_3)$ δ =1.08, 1.12(28, Si-CH(CH₃)₂), 3.66(s, 3, 2'-OCH₃), 3.72(d, 1, J_{2'-3'}=4Hz, H-2'), 4.02-4.30(4, H-3',4',5'), 5.64(d, 1, J₅₋₆=8Hz, H-5), 5.72(s, 1, H-1'), 7.88(d, 1, H-6), 10.10(br.s, 1, H-3). Found: C, 52.85; H, 8.34; N, 5.44%. Calcd for C₂₂H₄₀O₇N₂Si₂: C, 52.77; H, 8.05; N, 5.59%.

Desilylation from 6 (93 mg, 0.186 mmole) was performed by use of potassium fluoride (62.5 mg, 1.12 mmole) and tetraethylammonium chloride (234 mg, 1.12 mmole) in aqueous acetonitrile(67:1 v/v, 4.06 ml) at 53°C for 0.5 h⁹⁾. 2'-O-Methyluridine (7) was obtained in 69% yield which was estimated by UV absorption. (ϵ_{263} =10,100^{4b)} in 95% EtOH).

$^1\text{H-NMR}(\text{D}_2\text{O}/t\text{-BuOH internal})$ δ =3.60(s, 3, 2'-OCH₃), 3.72-4.44(5, H-2',3',4',5'), 5.94(d, 1, J₅₋₆=8Hz, H-5), 6.00(d, 1, J_{1'-2'}=4Hz, H-1'), 7.96(d, 1, H-6).

Quite recently, Reese¹⁰⁾ has reported the protection of imide and amide group with aryl group. The application of TCBoc-protected uridine unit to the oligoribonucleotide synthesis is now in progress.

References

- 1) J. F. W. McOmie, Ed. "Protective Groups in Organic Chemistry", Plenum Press, London, (1973), p. 403.
M. Miyaki, A. Saito, and B. Shimizu, Chem. Pharm. Bull., 18, 2459 (1970).
T. Azuma and K. Isono, Chem. Pharm. Bull., 25, 3347 (1977).
J. A. Montgomery and H. J. Thomas, J. Org. Chem., 46, 594 (1981).
- 2) P. K. Bridson, W. T. Markiewicz, and C. B. Reese, J. Chem. Soc. Chem. Commun., 1977, 791.
C. B. Reese and A. Ubasawa, Nucleic Acids Res. Symposium Series No. 7, 5 (1980).
C. B. Reese and A. Ubasawa, Tetrahedron Lett., 21, 2265 (1980).
B. Rayner, C. B. Reese, and A. Ubasawa, J. Chem. Soc. Chem. Commun., 1980, 972.
- 3) H. P. Daskalov, M. Sekine, and T. Hata, Tetrahedron Lett., 21, 3899 (1980).
Idem, Bull. Chem. Soc. Jpn., 54, 3076 (1981).
- 4) a) Y. Furukawa, K. Kobayashi, Y. Kanai, and M. Honjo, Chem. Pharm. Bull., 13, 1273 (1965).
b) D. M. G. Martin, C. B. Reese, and G. F. Stephenson, Biochemistry, 7, 1406 (1968).
c) J. T. Kuśmierek, J. Giziewicz, and D. Shugar, Biochemistry, 12, 194 (1973).
d) A. H. Hains, Tetrahedron, 29, 2807 (1973).
e) M. J. Robins, S. R. Naik, and A. S. K. Lee, J. Org. Chem., 39, 1891 (1974).
- 5) H. Eckert, M. Listl, and I. Ugi, Angew. Chem. Int. Ed. Engl., 17, 361 (1978).
- 6) W. T. Markiewicz and M. Wiewiórowski, Nucleic Acids Res., Spec. publ. No. 4, s 185 (1978).
W. T. Markiewicz, J. Chem. Res. (s), 24 (1979).
- 7) C. B. Reese and J. C. M. Stewart, Tetrahedron Lett., 1968, 4273.
- 8) R. W. Adamiak, E. B. K. Grzeńkowiak, R. Kierzek, A. Kraszewski, W. T. Markiewicz, J. Stawiński, and M. Wiewiórowski, Nucleic Acids Res., 4, 2321 (1977).
- 9) S. Honda, K. Terada, Y. Sato, M. Sekine, and T. Hata, Chem. Lett., 1982, 15.
- 10) S. S. Jones, C. B. Reese, S. Sibanda, and A. Ubasawa, Tetrahedron Lett., 22, 4755 (1981).

(Received April 10, 1982)